New vaccine aims to shield older adults from pneumonia
NCT ID NCT07105722
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new vaccine called Pn-MAPS30plus to see if it is safe and helps the body fight pneumonia-causing bacteria. It involved 127 healthy adults aged 50 to 64. The vaccine is designed to protect against more types of the bacteria than current vaccines.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMOCOCCAL INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
GSK Investigational Site
Norwood, South Australia, 5067, Australia
-
GSK Investigational Site
Bayswater, Victoria, 3153, Australia
-
GSK Investigational Site
Camberwell, Victoria, 3124, Australia
-
GSK Investigational Site
East Melbourne, Victoria, 3002, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI could outsmart bacteria: a smarter way to choose antibiotics?
- Does the setting of care affect whether kids finish their antibiotics?
- Inhaled antibiotics aim to beat pneumonia in ECMO patients
- Which works better: one antibiotic or two for this superbug?
- Broader pneumonia protection for babies? new vaccine trial shows promise
- One-Hour test could revolutionize pneumonia treatment in hospitals